ABOUT US

New Cures Need
New Strategies

Exponential reductions in the cost of DNA sequencing, combined with the advanced computational methods of machine learning & artificial intelligence (ML/AI), will inevitably disrupt the costly & time-consuming process of finding cures for difficult-to-treat diseases. Haystack Sciences is at the forefront of this evolution.

Haystack’s proprietary methods for synthesizing, breeding, and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences (DNA-Encoded Libraries, or DELs) establishes a revolutionary, data-intensive platform for discovering new cures for difficult-to-treat disorders.

 
TECHNOLOGY
 

Convergent Sampling

Haystack Sciences accelerates pharmaceutical development using

DNA-templated combichem libraries
Advanced computational methods for library characterization
An experimental algorithm (nDexer™) for compound ranking

 
Templated Synthesis
+
 

 
DEL Evolution
+
 
nDexer
+
 
TECHNOLOGY

Haystack Sciences Platform

Haystack Sciences’ DNA-Encoded Libraries couple synthetic chemistry with Darwinian selection to evolve drug candidates.


DNA is at The Heart of Biology


By connecting DNA directly to chemistry, Haystack’s technology enables the rapid discovery and refinement of new therapeutic molecules through molecular breeding.

What's more, Haystack’s experimental algorithm, nDexer™, is capable of unprecedented data extraction from DELs of all scales.

 
THE TEAM

The People Behind Haystack Sciences

Haystack have deep expertise in technology development and commercialization.

Eddie Ray Watts

FOUNDER, CEO


Divya Kanichar

FOUNDER, OPERATIONS